Hospital Acquired Infection Control Market Analysis and Forecast to 2032: By Product & Services (Sterilization, Cleaning & Disinfection Products, Protective Barriers, Endoscope Reprocessing Products), Infection Type (Hospital-acquired Pneumonia, Bloodstre

Hospital Acquired Infection Control Market Analysis and Forecast to 2032: By Product & Services (Sterilization, Cleaning & Disinfection Products, Protective Barriers, Endoscope Reprocessing Products), Infection Type (Hospital-acquired Pneumonia, Bloodstream Infections, Surgical Site Infections, Gastrointestinal Infections, Urinary Tract Infections, Others), End-user (Hospitals & Clinics, Ambulatory Surgical Centers, Others), and Others

The hospital-acquired infection control market was valued at USD 19.0 billion in 2022 and it is anticipated to grow further up to USD 26.8 billion by 2032, at a CAGR of 3.5% during the forecast period.

Nosocomially acquired illnesses that are not present or incubating at the time of admission to a hospital are known as hospital-acquired infections (HAIs). These infections include bloodstream infections linked to central lines, urinary tract infections linked to catheters, surgical site infections, pneumonia linked to ventilators, pneumonia acquired in hospitals, and infections with Clostridium difficile. A productive cough, shortness of breath, abdominal discomfort, rebound tenderness, altered mental status, palpitations, suprapubic pain, polyuria, dysuria, and costovertebral angle tenderness are signs that an infection is present.

Global Hospital Acquired Infection Control Market Scope and Report Structure

Market Trends and Drivers

Some of the major factors driving this market are rising awareness about Hospital Acquired Infections (HAIs), the need to prevent cross-infections, the incidence of infectious diseases in healthcare facilities, and supportive government programs to encourage infection control techniques. The development of national, regional, and hospital-level infection prevention guidelines and policies as well as the expanding use of monitoring tools are both contributing to the expansion. Similarly, the market for hospital-acquired infection control is anticipated to grow as a result of factors including the increased demand for sterilization and disinfection in hospitals and clinics, technological developments in sterilization and disinfection equipment, an increase in hospitals outsourcing sterilization services to pharmaceutical and medical device companies, and an increase in the production of medical nonwovens and single-use products due to an increase in COVID-19 cases.

Market Restraints and Challenges

The market for hospital acquired infection control is predicted to rise, but this expansion is expected to be constrained by the negative effects of chemical disinfectants and worries about the safety of reprocessed instruments. In contrast, it is anticipated that the growing use of single-use medical nonwovens and devices would present profitable prospects during the projection period.

Global Hospital Acquired Infection Control Market Segmental Overview

The report analyses the global hospital acquired infection control market based on product & services, infection type, end user, and region.

Global Hospital Acquired Infection Control Market by Product & Services

Based on the product & services, it is segmented into sterilization, cleaning & disinfection products, protective barriers, and endoscope reprocessing products. The protective barrier segment is anticipated to dominate the market during the forecast period. This is attributed to an increase in the general public's awareness of personal hygiene, an increase in surgical procedures, a rise in the use of medical nonwovens, such as face masks, surgical drapes, and gowns, as a result of an increase in COVID-19 cases, and an increase in the manufacturing of gloves and nonwoven products.

Global Hospital Acquired Infection Control Market by Infection Type

Based on the infection type, it is segmented into hospital-acquired pneumonia, bloodstream infections, surgical site infection, gastrointestinal infections, urinary tract infections, and others. The hospital-acquired pneumonia segment is expected to dominate the market during the forecast period. Some of the major factors driving this market include rising awareness regarding Hospital Acquired Infections (HAIs), the requirement to prevent cross-infections, the prevalence of infectious diseases in healthcare facilities, and encouraging government initiatives to promote infection control practices.

Global Hospital Acquired Infection Control Market by End User

Based on the end user, it is segmented into hospitals & clinics, ambulatory surgical centers, and others. The hospitals & clinics segment is the major shareholder in the hospital-acquired infection control market. Due to an increase in the number of surgical procedures performed in hospitals, an increase in the prevalence of hospital-acquired infections, an increase in the number of hospitals and clinics, and an increase in the number of elderly people, who also have an increase in the prevalence of chronic illnesses.

Geographical Analysis of the Global Hospital Acquired Infection Control Market

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America dominated the market and accounted for the largest revenue share in 2022. The presence of important companies, the initiatives they launched in the public and private sectors, and the rising awareness of HAIs in this area are all factors that contribute to the big share. For instance, the American-based Ecolab purchased the Swiss company vanBaerle Hygiene AG in December 2020. This expanded the product portfolio and service capabilities of Ecolab by providing a broad spectrum of cleaning, disinfection, and hygiene solutions. The CDC is in charge of epidemic investigations, surveillance, research, and HAI prevention in the United States. In accordance with the HHS Action Plan to Avoid Healthcare-Associated Infections in Acute Care Hospitals, the CDC also develops novel methods to prevent infections related to healthcare. In the upcoming years, it is anticipated that supportive measures like these will fuel regional growth.

Major Players of the Global Hospital Acquired Infection Control Market

The key players analyzed in the market are Olympus Corporation, Medivators Inc. (Cantel Medical Corp.), Getinge Group, STERIS Plc., Belimed AG (Metall Zug), Steelco S.P.A, Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Advanced Sterilization Products Services Inc. (Johnson & Johnson), Abbott Laboratories, and Bayer AG among others.

COVID-19 Impact

The hospital-acquired infection control market was significantly impacted by the COVID-19 epidemic. In particular, hand sanitizers, disinfectants, PPE kits, masks, and gloves saw a spike in demand as a result. The prior year saw an increase in the demand for infection control goods and services. For instance, the Metall Zug Group disclosed the negative effects of the COVID-19 pandemic on its total company in August 2020. The corporation did see an increase in its infection control business division, though.

Hospital acquired infections during the outbreak were observed to have decreased statistically significantly, according to a 2020 study on the Impact of the COVID-19 Pandemic on the HAI Rate in Iran. High employment of infection control technology, adherence to infection control procedures, isolation of infected patients, and the use of antimicrobial treatments to eradicate infection were all factors in the low occurrence of HAIs. The study also discovered that the low occurrence of nosocomial infections was due in part to increased awareness, ongoing education, and the use of suitable and effective infection control measures.

Recent Development

September 2021, Sodexo has expanded its partnership with Ecolab in the United States for the control of hospital-acquired infections through the Protecta Plus programme. This programme was created to reduce infection risk in hospitals and healthcare facilities by utilizing Ecolab's Bioquell hydrogen peroxide vapor technology.

July 2021, UVision 360 Inc. announced that it had received approval for the expansion of reprocessing procedures for utilization with the Luminelle DTx system.

April 2020, Allegheny Health Network (AHN), announced a sterilization process that would allow the reuse of N95 masks that were very crucially in demand.

April 2020, Steris received Emergency Use Authorization (EUA) from the U.S. FDA for respirator decontamination. This allowed the company to temporarily offer a solution for decontamination of compatible N95 or N95-equivalent respirators using STERIS V-PRO Low Temperature Sterilization Systems.

Hospital Acquired Infection Control Market Report Coverage

The report offers a comprehensive quantitative as well as qualitative analysis of the current Hospital Acquired Infection Control Market outlook and estimations from 2022 to 2032, which helps to recognize the prevalent opportunities.

The report also covers qualitative as well as quantitative analysis of the Hospital Acquired Infection Control Market in terms of revenue ($Million).

Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the Hospital Acquired Infection Control Market industry.

A thorough analysis of market trends and restraints is provided.

By region as well as country market analysis is also presented in this report.

Analytical depiction of the Hospital Acquired Infection Control Market along with the current trends and future estimations to depict imminent investment pockets. The overall Hospital Acquired Infection Control Market Industry opportunity is examined by understanding profitable trends to gain a stronger foothold.

Porter’s five forces analysis, SWOT analysis, Pricing Analysis, Case Studies, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Hospital Acquired Infection Control Market are also analyzed.

Frequently Asked Questions

Q1. How big is the Hospital Acquired Infection Control market?

Ans. The global Hospital Acquired Infection Control market size was USD 19.0 billion in 2022 and is anticipated to reach USD 26.8 billion in 2032, growing at a rate of 3.5% from 2023 to 2032.

Q2. What is the Hospital Acquired Infection Control market growth rate?

Ans. The growth rate of the Hospital Acquired Infection Control market is 3.5%.

Q3. Which region holds a major market share for the Hospital Acquired Infection Control market?

Ans. North America holds a major market share of the Hospital Acquired Infection Control market in 2021.

Q4. Which segment accounted for the largest Hospital Acquired Infection Control market share?

Ans. By end user, hospitals & clinics segment accounted for the largest Hospital Acquired Infection Control market share.

Q5. Who are the key players in the Hospital Acquired Infection Control market?

Ans. The global Hospital Acquired Infection Control market report includes players such as Olympus Corporation, Medivators Inc. (Cantel Medical Corp.), Getinge Group, STERIS Plc., Belimed AG (Metall Zug), Steelco S.P.A, Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Advanced Sterilization Products Services Inc. (Johnson & Johnson), Abbott Laboratories, and Bayer AG among others.

Q6. What are the factors driving the Hospital Acquired Infection Control market growth?

Ans. The major factors driving the growth of the market are the growing healthcare market in emerging countries.

Q7. What are the key growth strategies of Hospital Acquired Infection Control market players?

Ans. The key growth strategies of Hospital Acquired Infection Control market players are product launch and product approval.

Q8. Which region will provide more business opportunities for the Hospital Acquired Infection Control market during the forecast period?

Ans. The Asia-Pacific region will provide more business opportunities for the Hospital Acquired Infection Control market during the forecast period.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.